Edgar Filing: HOMBACH ROBERT J. - Form 4

HOMBACH RC Form 4	DBERT J.										
June 14, 2018											
	1									PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check this bo			0 /					Expires:	January 31,		
if no longer subject to Section 16. Form 4 or	ENT OF C	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Estimated average burden hours per response 0.5			
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940											
(Print or Type Resp	onses)										
1. Name and Address of Reporting Person <u>*</u> HOMBACH ROBERT J.			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
C/O BIOMARI PHARMACEU DIGITAL DRI	TICAL INC., 1		6/05/20	18				below)	below)		
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line)			
NOVATO, CA	94949							_X_ Form filed by Form filed by I Person	One Reporting Pe More than One Re		
(City)	(State) (Z	iip)	Table	I - Non-De	erivative S	Securi	ties Aco	quired, Disposed o	f, or Beneficial	lly Owned	
	Transaction Date Aonth/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securi nAcquired Disposed (Instr. 3,	l (A) o l of (D))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common 00 Stock 00	6/05/2018 <u>(1)</u>			А	4,300	А	\$ 0 (2)	7,480	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Other

Edgar Filing: HOMBACH ROBERT J. - Form 4

Reporting Owners

**Signature of Reporting Person

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer			
HOMBACH ROBERT J. C/O BIOMARIN PHARMACEUTICAL II 105 DIGITAL DRIVE NOVATO, CA 94949	NC.	Х					
Signatures							
/s/ Eric Fleekop, Attorney-in-Fact	/14/20	18					

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction, originally due to be reported on Thursday, June 7, 2018, is being reported late due to an administrative oversight.
- (2) Restricted stock units granted on June 5, 2018. Price not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.